Plain-English translation of NCT05168839 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a special fluorescence imaging technique using indocyanine green can help surgeons prevent a serious complication after colorectal cancer surgery. The technique involves injecting a safe dye that helps the surgeon see blood flow to the area where the bowel is reconnected during surgery. Half of participants will have this imaging technique used during their surgery, and half will have standard surgery without it.
After colorectal cancer surgery, about 1 in 14 patients develop a leak at the surgical connection site, which can be life-threatening and requires additional treatment. Researchers believe this new imaging technique might help surgeons identify areas at risk and prevent this complication from happening.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will undergo your scheduled colorectal cancer surgery at one of 26 participating French hospitals. You will be randomly assigned to either receive the new fluorescence imaging technique during your surgery or standard surgery without it. After surgery, you will be followed for 90 days to monitor whether you develop any complications at the surgical connection site.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
France